TITLE

Clinical practice guidelines for the care and treatment of breast cancer: adjuvant systemic therapy for node-negative breast cancer (summary of the 2001 update)

AUTHOR(S)
Levine, Mark
PUB. DATE
January 2001
SOURCE
CMAJ: Canadian Medical Association Journal;1/23/2001, Vol. 164 Issue 2, p213
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Provides a summary of changes made by the Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer to an article regarding clinical practice guidelines for adjuvant systemic therapy for women with node-negative breast cancer. Changes in the percentages of women with risk reduction and mortality after treatment with chemotherapy and tamoxifen; Comparison of tamoxifen plus chemotherapy with chemotherapy alone.
ACCESSION #
4017168

 

Related Articles

  • Clinical practice guidelines for the care and treatment of breast cancer: adjuvant systemic therapy for node-positive breast cancer (summary of the 2001 update). Levine, Mark // CMAJ: Canadian Medical Association Journal;3/06/2001, Vol. 164 Issue 5, p644 

    Discusses changes to Health Canada's Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer. Revised recommendations regarding the types of chemotherapy regimens for pre-menopausal women, the use of tamoxifen in premenopausal women and the use of...

  • Chemotherapy and hormonal treatments improve the 15 year survival rate for breast cancer. Mayor, Susan // BMJ: British Medical Journal (International Edition);5/21/2005, Vol. 330 Issue 7501, p1167 

    Examines the impact of chemotherapy and hormonal treatments on the long-term survival of breast cancer patients. Results of a study showing that chemotherapy and hormonal therapy achieve positive results in the 15-year survival of patients; Details of the study, performed by the Early Breast...

  • Tamoxifen lowers death rates from contralateral breast cancer.  // Modern Medicine;Jul95, Vol. 63 Issue 7, p33 

    Reports on the effect of tamoxifen citrate in reducing mortality caused by contralateral breast cancer according to Joseph Ragaz. Data collection; Dosage regimen; Calculation of the overall survival impact; Monitoring signs of vaginal discharge.

  • New indication for tamoxifen: Male breast cancer. Rodman, Morton J.; Hurley, Mary Lou // RN;Nov93, Vol. 56 Issue 11, p87 

    Reports on the effectiveness of tamoxifen in treating advanced metastatic breast cancer in men. Dosage for men and women with breast cancer; Adverse effects; Positive results in men with low sperm counts.

  • Tamoxifen effects on subjective and psychosexual well-being, in a randomised breast cancer study comparing high-dose and standard-dose chemotherapy. Mourits, M.J.; Bockermann, I.; de Vries, E.G.; van der Zee, A.G.; ten Hoor, K.A.; van der Graaf, W.T.; Sluiter, W.J.; Willemse, P.H. // British Journal of Cancer;5/20/2002, Vol. 86 Issue 10, p1546 

    To evaluate the impact of tamoxifen on subjective and psychosexual well-being in breast cancer patients in relation to type of prior chemotherapy and menopausal status. Longitudinal interview study in breast cancer patients during and after adjuvant tamoxifen use. Menopausal status was defined...

  • Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer. Fisher, Bernard; Dignam, James // JNCI: Journal of the National Cancer Institute;11/19/97, Vol. 89 Issue 22, p1673 

    Examines the effectiveness of chemotherapy plus tamoxifen in the treatment of patients with axillary lymph node-negative, estrogen receptor-positive breast cancer. Survival rate of patients using the combined treatment than patients using tamoxifen alone; Reduction in the risk of ipsilateral...

  • We told you so.  // Herizons;Fall98, Vol. 12 Issue 3, p11 

    Reports on the use of the drug Tamoxifen as a preventive treatment for breast cancer. Results of a study in North America which suggested that the drug reduced the incidence of breast cancer; British scientists' conclusion that the drug does not prevent breast cancer; Side effects of the drug.

  • Recurrent breast cancer treated with the antioestrogen tamoxifen: correlation between hormonal changes and clinical course. Willis, K.J.; London, D.R.; Ward, H.W.C.; Butt, W.R.; Lynch, S.S.; Rudd, B.T. // British Medical Journal;2/12/1977, Vol. 1 Issue 6058, p425 

    Examines the incidence of recurrent breast cancer in menopausal women treated with antioestrogen tamoxifen in Great Britain. Correlation between hormonal change and the clinical course of cancer; Suppression of gonadotrophins; Determination of luteinizing hormone-releasing hormone response.

  • Update '98.  // Mayo Clinic Health Letter;Jul1998, Vol. 16 Issue 7, p4 

    Focuses on the use of tamoxifen or raloxifene drugs to prevent cancer of the breast. Reason Mayo Clinic oncologists are cautious about using these drugs for breast cancer prevention; Information on tamoxifen and raloxifene; Results of studies conducted on the two synthetic compounds.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics